You are here: Home: Audio Program Guide: LCU Think Tank 1 | 2006: LCU Think Tank 1 | 2006 Audio
  Go to Management of Metastatic NSCLC
Go to Factors to Consider in the Treatment of NSCLC
Go to Adjuvant Therapy for NSCLC
Go to Management of Stage III NSCLC

   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
  Management of Metastatic NSCLC

  
  Click here to download entire section  
Track 1 Introduction
Track 2 First-line therapy of advanced non-small cell lung cancer (NSCLC)
Track 3 Toxicity and side effects associated with bevacizumab in ECOG-E4599
Track 4 Selection of a chemotherapeutic regimen to combine with bevacizumab
Track 5 Impact of tumor location on incidence of hemoptysis with bevacizumab
Track 6 Rationale for the continuation of bevacizumab until disease progression
Track 7 Side effects associated with bevacizumab
Track 8 Risk factors for bevacizumab-associated pulmonary hemorrhage
Track 9 Weighing the risks and benefits of bevacizumab for patients with metastatic NSCLC
Track 10 Potential predictors of response to bevacizumab
Track 11 Counseling patients about the risks and benefits of bevacizumab
Track 12 Factors affecting the selection of patients for treatment with bevacizumab
Track 13 ECOG-E1505: Cisplatin-based chemotherapy with or without bevacizumab in the adjuvant setting
Track 14 Efficacy and tolerability of bevacizumab in combination with erlotinib
Track 15 Ongoing and completed trials examining the role of ZD6474 in NSCLC
Track 16 Clinical use of bevacizumab in combination with erlotinib
Track 17 Bevacizumab in patients with brain metastases
 
  Factors to Consider in the Treatment of NSCLC

  
  Click here to download entire section  
Track 1 Treatment for patients with poor performance status
Track 2 Predictors of response to anti-EGFR therapy
Track 3 Clinical use of EGFR mutation testing
Track 4 Role of adjuvant erlotinib in patients with EGFR gene mutations or in never smokers
Track 5 Lack of clinical trial data regarding the use of adjuvant erlotinib
Track 6 Erlotinib as first-line therapy for patients with EGFR gene mutations
Track 7 Current limitations of predictors of response to anti-EGFR therapy
Track 8 Classifying and treating never smokers
Track 9 Importance of factoring smoking history into treatment decision-making
Track 10 Fraction of lung cancer patients who are smokers at the time of diagnosis
 
  Adjuvant Therapy for NSCLC

  
  Click here to download entire section  
Track 1 Updated results from CALGB-9633 trial of adjuvant chemotherapy for Stage IB disease
Track 2 Adjuvant chemotherapy for patients with Stage I disease
Track 3 Clinical implications of CALGB-9633 results
Track 4 Impact of CALGB-9633 on the design of future adjuvant trials
Track 5 Selection of an adjuvant chemotherapeutic regimen
Track 6 Management of Stage IB disease
Track 7 Importance of a full mediastinal lymph node dissection in the surgical management of lung cancer
Track 8 Tolerability of chemotherapy in elderly patients
Track 9 Clinical use of bevacizumab in elderly patients
Track 10 Role of age in the selection of a treatment regimen
Track 11 Current controversies in the use of adjuvant therapy for NSCLC
Track 12 Challenges of launching adjuvant clinical trials with bevacizumab in lung cancer
Track 13 Rationale for conducting adjuvant trials with bevacizumab
 
  Management of Stage III NSCLC

  
  Click here to download entire section  
Track 1 RTOG-0412/SWOG-S0332: Preoperative cisplatin/docetaxel with or without radiation therapy followed by surgical resection and consolidation docetaxel in patients with Stage IIIA disease
Track 2 Entry criteria and quality control measures for RTOG-0412/SWOG-S0332
Track 3 Rationale for poor accrual to the RTOG-0412/SWOG-S0332 trial
Track 4 Lack of definitive data about the role of preoperative chemotherapy with radiation therapy for Stage III disease
Track 5 Benefit of surgery after induction chemotherapy and radiation therapy in the management of Stage III disease
Track 6 Surgery after induction chemotherapy for Stage III patients with a positive mediastinum
Track 7 Role of reassessing the mediastinum after induction chemotherapy and radiation therapy
Track 8 Endobronchial ultrasound to evaluate residual mediastinal disease
Track 9 Quality control with radiation therapy
Track 10 SWOG-S0023: Cisplatin/etoposide/radiation therapy followed by consolidation docetaxel with or without gefitinib maintenance for Stage III disease
Track 11 Tolerability of consolidation docetaxel following cisplatin/etoposide/radiation therapy
Track 12 SWOG 0533: Cisplatin/etoposide/radiation therapy followed by consolidation docetaxel and bevacizumab in three cohorts of patients with inoperable locally advanced Stage III disease
Track 13 Clinical use of cisplatin/etoposide/radiation therapy followed by consolidation docetaxel
Track 14 Use of growth factor support in patients receiving chemotherapy with radiation therapy